Heart 2001;86:527-532 ( November )

Cardiovascular medicine

Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: the GISSI-3 data F Pizzetti^b, F M Turazza^a, M G Franzosi^a, S Barlera^a, A Ledda^c, A P Maggioni^d, L Santoro^a, G Tognoni^a, on behalf of the GISSI-3 Investigators

^a Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy, ^b Division of Cardiology, S Spirito Hospital, Casale Monferrato (AL), Italy, ^c Division of Cardiology, Cervello Hospital, Palermo, Italy, ^d Centro Studi, ANMCO, Florence, Italy

Correspondence to: Dr F M Turazza, GISSI Coordinating Centre, Department of Cardiovascular Research, Istituto di Ricerche Farmacologiche Mario Negri, Via Eritrea 62, 20157 Milan, Italy depcardio{at}irfmn.mnegri.it

Accepted 11 July 2001

BACKGROUNDAtrial fibrillation is the most common supraventricular arrhythmia in patients with acute myocardial infarction. Recent advances in pharmacological treatment of myocardial infarction may have changed the impact of this arrhythmia.
OBJECTIVETo assess the incidence and prognosis of atrial fibrillation complicating myocardial infarction in a large population of patients receiving optimal treatment, including angiotensin converting enzyme (ACE) inhibitors.
METHODSData were derived from the GISSI-3 trial, which included 17 944 patients within the first 24 hours after acute myocardial infarction. Atrial fibrillation was recorded during the hospital stay, and follow up visits were planned at six weeks and six months. Survival of the patients at four years was assessed through census offices.
RESULTSThe incidence of in-hospital atrial fibrillation or flutter was 7.8%. Atrial fibrillation was associated with indicators of a worse prognosis (age > 70 years, female sex, higher Killip class, previous myocardial infarction, treated hypertension, high systolic blood pressure at entry, insulin dependent diabetes, signs or symptoms of heart failure) and with some adverse clinical events (reinfarction, sustained ventricular tachycardia, ventricular fibrillation). After adjustment for other prognostic factors, atrial fibrillation remained an independent predictor of increased in-hospital mortality: 12.6% v 5%, adjusted relative risk (RR) 1.98, 95% confidence interval (CI) 1.67 to 2.34. Data on long term mortality (four years after acute myocardial infarction) confirmed the persistent negative influence of atrial fibrillation (RR 1.78, 95% CI 1.60 to 1.99).
CONCLUSIONSAtrial fibrillation is an indicator of worse prognosis after acute myocardial infarction, both in the short term and in the long term, even in an unselected population.


Keywords: atrial fibrillation; acute myocardial infarction; prognosis

---

© 2001 by Heart
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

• Lopes, R. D., Elliott, L. E., White, H. D., Hochman, J. S., Van de Werf, F., Ardissino, D., Nielsen, T. T., Weaver, W. D., Widimsky, P., Armstrong, P. W., Granger, C. B. (2009). Antithrombotic therapy and outcomes of patients with atrial fibrillation following primary percutaneous coronary intervention: results from the APEX-AMI trial. Eur Heart J 30: 2019-2028 [Abstract] [Full Text]  
• Schmitt, J., Duray, G., Gersh, B. J., Hohnloser, S. H. (2009). Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 30: 1038-1045 [Abstract] [Full Text]  
• The GISSI-AF Investigators, (2009). Valsartan for Prevention of Recurrent Atrial Fibrillation. NEJM 360: 1606-1617 [Abstract] [Full Text]  
• Dorian, P., Singh, B. N. (2008). Upstream therapies to prevent atrial fibrillation. Eur Heart J Suppl 10: H11-H31 [Abstract] [Full Text]  
• Lopes, R D, Pieper, K S, Horton, J R, Al-Khatib, S M, Newby, L K, Mehta, R H, Van de Werf, F, Armstrong, P W, Mahaffey, K W, Harrington, R A, Ohman, E M, White, H D, Wallentin, L, Granger, C B (2008). Short- and long-term outcomes following atrial fibrillation in patients with acute coronary syndromes with or without ST-segment elevation. Heart 94: 867-873 [Abstract] [Full Text]  
• Sakabe, M., Shiroshita-Takeshita, A., Maguy, A., Brundel, B. J.J.M., Fujiki, A., Inoue, H., Nattel, S. (2008). Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 78: 63-70 [Abstract] [Full Text]  
• Casaclang-Verzosa, G., Gersh, B. J., Tsang, T. S.M. (2008). Structural and functional remodeling of the left atrium: clinical and therapeutic implications for atrial fibrillation.. J Am Coll Cardiol 51: 1-11 [Abstract] [Full Text]  
• Kober, L., Swedberg, K., McMurray, J. J.V., Pfeffer, M. A., Velazquez, E. J., Diaz, R., Maggioni, A. P., Mareev, V., Opolski, G., Van de Werf, F., Zannad, F., Ertl, G., Solomon, S. D., Zelenkofske, S., Rouleau, J.-L., Leimberger, J. D., Califf, R. M. (2006). Previously known and newly diagnosed atrial fibrillation: A major risk indicator after a myocardial infarction complicated by heart failure or left ventricular dysfunction. Eur J Heart Fail 8: 591-598 [Abstract] [Full Text]  
• Ehrlich, J. R., Hohnloser, S. H., Nattel, S. (2006). Role of angiotensin system and effects of its inhibition in atrial fibrillation: clinical and experimental evidence. Eur Heart J 27: 512-518 [Abstract] [Full Text]  
• Pedersen, O. D., Abildstrom, S. Z., Ottesen, M. M., Rask-Madsen, C., Bagger, H., Kober, L., Torp-Pedersen, C., on behalf of the TRACE study investigators, (2006). Increased risk of sudden and non-sudden cardiovascular death in patients with atrial fibrillation/flutter following acute myocardial infarction. Eur Heart J 27: 290-295 [Abstract] [Full Text]  
• Krumholz, H. M., Anderson, J. L., Brooks, N. H., Fesmire, F. M., Lambrew, C. T., Landrum, M. B., Weaver, W. D., Whyte, J., Bonow, R. O., Bennett, S. J., Burke, G., Eagle, K. A., Krumholz, H. M., Lambrew, C. T., Linderbaum, J., Masoudi, F. A., Normand, S.-L. T., PiNa, I. L., Radford, M. J., Rumsfeld, J. S., Ritchie, J. L., Spertus, J. A. (2006). ACC/AHA Clinical Performance Measures for Adults With ST-Elevation and Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology/American Heart Association Task Force on Performance Measures (Writing Committee to Develop Performance Measures on ST-Elevation and Non-ST-Elevation Myocardial Infarction). J Am Coll Cardiol 47: 236-265 [Full Text]  
• Boos, C. J., Anderson, R. A., Lip, G. Y.H. (2006). Is atrial fibrillation an inflammatory disorder?. Eur Heart J 27: 136-149 [Abstract] [Full Text]  
• Kalus, J. S., Coleman, C. I., White, C. M. (2006). The Impact of Suppressing the Renin-Angiotensin System on Atrial Fibrillation. J Clin Pharmacol 46: 21-28 [Abstract] [Full Text]  
• Healey, J. S., Baranchuk, A., Crystal, E., Morillo, C. A., Garfinkle, M., Yusuf, S., Connolly, S. J. (2005). Prevention of Atrial Fibrillation With Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers: A Meta-Analysis. J Am Coll Cardiol 45: 1832-1839 [Abstract] [Full Text]  
• McMurray, J., Kober, L., Robertson, M., Dargie, H., Colucci, W., Lopez-Sendon, J., Remme, W., Sharpe, D. N., Ford, I. (2005). Antiarrhythmic effect of carvedilol after acute myocardial infarction: Results of the Carvedilol Post-Infarct Survival Control in Left Ventricular Dysfunction (CAPRICORN) trial. J Am Coll Cardiol 45: 525-530 [Abstract] [Full Text]  
• Lehto, M., Snapinn, S., Dickstein, K., Swedberg, K., Nieminen, M. S., on behalf of the OPTIMAAL investigators, (2005). Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 26: 350-356 [Abstract] [Full Text]